⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

February 15, 2024Frontiers in PharmacologyOpen Access

The effectiveness of oral anti-SARS-CoV-2 agents in non-hospitalized COVID-19 patients with nonalcoholic fatty liver disease: a retrospective study

Chun‐Chi Yang Ya‐Wen Tsai Su‐Hung Wang Jheng‐Yan Wu Ting-Hui Liu Wan‐Hsuan Hsu Po‐Yu Huang Min‐Hsiang Chuang Ming‐Jen Sheu Chih‐Cheng Lai

View Full Paper

Ask AI

Bookmark

Share

Abstract

The effectiveness of the novel oral antiviral agents, nirmatrelvir plus ritonavir and molnupiravir, in treating COVID-19 in patients with nonalcoholic fatty liver disease is unclear.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yang et al. (2024) studied this question.

synapsesocial.com/papers/68e7907ab6db64358770168c https://doi.org/10.3389/fphar.2024.1321155

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The effect of oral antiviral therapy for COVID-19 in managing non-hospitalized patients with lung cancer2024
2Clinical effectiveness of oral antiviral agents for treating non-hospitalized COVID-19 patients with chronic kidney disease2024 · 3 citations
3Effectiveness of recently-approved oral antiviral medications on the outcome of patients with mild-to-moderate COVID-19 and pre–existing chronic obstructive pulmonary diseases2024 · 1 citations
4The effectiveness of novel oral antiviral treatment for non-hospitalized high-risk patients with COVID-19 during predominance of omicron XBB subvariants2024 · 4 citations
5Newer Oral Antiviral for the Treatment of COVID-19 Infection2024 · 1 citations